TY  - JOUR
AU  - Zozaya, Néboa
AU  - Abdalla, Fernando
AU  - Alfonso Zamora, Santiago
AU  - Balea Filgueiras, Jesús
AU  - Carrascosa Carrillo, José Manuel
AU  - Delgado Sánchez, Olga
AU  - Dolz Sinisterra, Francisco
AU  - García-Ruiz, Antonio
AU  - Herranz Pinto, Pedro
AU  - Manfredi, Antonio
AU  - Martínez Olmos, José
AU  - Morales de Los Ríos Luna, Paloma
AU  - Puig, Lluis
AU  - Ros, Sandra
AU  - HIdalgo-Vega, Álvaro
PY  - 2022
DO  - 10.1080/14737167.2022.2063842
UR  - http://hdl.handle.net/10668/19680
T2  - Expert review of pharmacoeconomics & outcomes research
AB  - Multi-criteria decision analysis (MCDA) was proposed to surmount arbitrary clinical decisions in the field of biological therapies for psoriatic patients. At the same time, MCDA may further highlight the potential of bimekizumab for the treatment of...
LA  - en
KW  - MCDA
KW  - Psoriasis
KW  - bimekizumab
KW  - biologics
KW  - moderate-to-severe
KW  - multi-criteria decision analysis
KW  - Adalimumab
KW  - Antibodies, Monoclonal, Humanized
KW  - Decision Support Techniques
KW  - Humans
KW  - Psoriasis
KW  - Severity of Illness Index
KW  - Treatment Outcome
TI  - Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis.
TY  - research article
VL  - 22
ER  -